VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
XOMA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
XOMAXOMA Royalty Corp.
$42.15$529M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksXOMAFinancials

XOMA Royalty Corp. (XOMA) Financials

30Y historyFree accessUpdated daily

Revenue remains highly volatile, evidenced by an 83.6% sequential decline in 2025Q4, even as the company maintains gross margins consistently exceeding 90%.

XOMA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue36.23M52.15M28.49M4.76M6.03M38.16M29.39M18.37M5.3M52.69M5.56M55.45M18.87M35.45M33.78M58.2M33.64M98.43M67.99M84.25M29.5M18.67M3.67M24.41M29.95M17.28M6.66M2.4M6.3M18.4M3.6M
Revenue Growth %-3.33%83.06%498.72%-21.06%-84.21%29.86%59.96%246.67%-89.94%846.98%-89.97%193.9%-46.78%4.94%-41.95%72.99%-65.82%44.78%-19.31%185.62%58.01%409.39%-84.99%-18.49%73.33%159.48%177.46%-61.9%-65.76%411.11%200%
Cost of Goods Sold2.43M2.96M206K143K274K171K170K1.25M1.68M7.88M1.4M20.7M29.47M27.36M143K000000016.37M0001.87M-1.2M-1.6M-2M-2.1M
COGS % of Revenue-5.68%0.72%3.01%4.55%0.45%0.58%6.82%31.74%14.95%25.16%37.33%156.19%77.18%0.42%-------446.74%---28.07%-50%-25.4%-10.87%-58.33%
Gross Profit33.8M49.18M28.28M4.62M5.75M37.99M29.21M17.12M3.62M44.81M4.16M34.75M-10.6M8.09M33.64M58.2M33.64M98.43M67.99M84.25M29.5M18.67M-12.71M24.41M29.95M17.28M4.79M3.6M7.9M20.4M5.7M
Gross Margin %93.29%94.3%99.28%96.99%95.45%99.55%99.42%93.18%68.26%85.05%74.84%62.67%-56.19%22.82%99.58%100%100%100%100%100%100%100%-346.74%100%100%100%71.93%150%125.4%110.87%158.33%
Gross Profit Growth %-73.89%512.81%-19.78%-84.86%30.03%70.68%373.24%-91.93%976.25%-88.02%427.77%-231.05%-75.95%-42.2%72.99%-65.82%44.78%-19.31%185.62%58.01%246.91%-152.06%-18.49%73.33%260.73%33.06%-54.43%-61.27%257.89%39.02%
Operating Expenses28.82M37.79M68.26M46.46M23.17M20.46M16.8M21M20.25M32.21M62.56M91.47M100.61M93.33M85.19M92.15M100.66M81.87M106.72M86.8M70.18M54.69M81.76M81.95M62.03M44.61M34.21M48.8M50.8M37.5M34M
OpEx % of Revenue-72.47%239.61%976.52%384.39%53.62%57.17%114.33%382.05%61.13%1124.3%164.97%533.31%263.26%252.17%158.35%299.23%83.17%156.97%103.02%237.92%292.97%2230.86%335.7%207.11%258.17%513.68%2033.33%806.35%203.8%944.44%
Selling, General & Admin39.8M36.09M34.48M27.18M23.19M20.46M16.8M21M18.56M24.34M18.32M20.62M19.87M18.48M16.86M24.01M23.25M23.74M24.14M20.58M18.09M14.8M31.98M24.49M19.41M8.68M6.07M6.1M5.4M5.6M5.5M
SG&A % of Revenue-69.21%121.03%571.27%384.79%53.62%57.17%114.33%350.31%46.19%329.3%37.19%105.3%52.12%49.92%41.26%69.11%24.11%35.51%24.43%61.32%79.27%872.5%100.32%64.79%50.24%91.14%254.17%85.71%30.43%152.78%
Research & Development468K1.71M2.88M143K153K171K170K1.25M1.68M7.88M44.23M70.85M80.75M74.85M68.32M68.14M77.41M58.13M82.58M66.22M52.09M39.9M49.78M57.46M42.62M35.93M30.01M41.5M43.8M29.9M26.4M
R&D % of Revenue-3.28%10.09%3.01%2.54%0.45%0.58%6.82%31.74%14.95%795%127.78%428.01%211.14%202.25%117.08%230.11%59.06%121.46%78.59%176.6%213.7%1358.36%235.38%142.31%207.93%450.61%1729.17%695.24%162.5%733.33%
Other Operating Expenses-1000K-11K30.9M19.14M-177K-171K-170K-1.25M4.34M1.11M1.51M44K-31K-197K0082K000000000-1.87M1.2M1.6M2M2.1M
Operating Income4.97M11.38M-39.98M-41.85M-17.41M17.53M12.42M-3.88M-16.86M17.03M-61.56M-39.72M-81.83M-58.2M-56.62M-33.95M-67.1M12.96M-38.73M-2.54M-40.68M-36.02M-78.1M-57.54M-32.08M-27.33M-29.42M-45.2M-42.9M-17.1M-28.3M
Operating Margin %13.73%21.83%-140.33%-879.53%-288.93%45.94%42.25%-21.15%-318.12%32.32%-1106.36%-71.64%-433.75%-164.18%-167.62%-58.35%-199.47%13.17%-56.97%-3.02%-137.92%-192.97%-2130.86%-235.7%-107.11%-158.17%-441.75%-1883.33%-680.95%-92.93%-786.11%
Operating Income Growth %-128.48%4.47%-140.31%-199.34%41.18%419.59%76.95%-198.98%127.67%-54.96%51.46%-40.59%-2.79%-66.76%49.4%-617.78%133.46%-1422.56%93.75%-12.93%53.87%-35.73%-79.37%-17.36%7.09%34.92%-5.36%-150.88%39.58%-7.6%
EBITDA8.29M14.36M-39.76M-40.95M-17.14M17.7M12.59M-3.86M-16.83M17.34M-60.79M-38.19M-79.98M-55.63M-52.5M-28.6M-61.38M19.79M-30.61M4.19M-34.51M-30.25M-73.54M-53.55M-29.96M-26.08M-31.29M-44M-41.3M-15.1M-26.2M
EBITDA Margin %22.9%27.53%-139.57%-860.61%-284.39%46.37%42.84%-21.01%-317.55%32.9%-1092.54%-68.88%-423.92%-156.92%-155.41%-49.14%-182.46%20.11%-45.03%4.97%-117%-162.04%-2006.63%-219.35%-100.03%-150.92%-469.82%-1833.33%-655.56%-82.07%-727.78%
EBITDA Growth %131.56%136.11%2.9%-138.9%-196.86%40.58%426.11%77.06%-197.07%128.52%-59.17%52.25%-43.76%-5.96%-83.58%53.41%-410.16%164.64%-830.67%112.14%-14.09%58.87%-37.34%-78.73%-14.89%16.65%28.9%-6.54%-173.51%42.37%-11.97%
D&A (Non-Cash Add-back)3.32M2.97M216K900K274K167K172K25K30K304K769K1.53M1.86M2.58M4.12M5.36M5.72M6.83M8.12M6.73M6.17M5.77M4.55M3.99M2.12M1.25M-1.87M1.2M1.6M2M2.1M
EBIT38.53M44.85M-5.64M-23.46M-17.12M16.35M13.64M-3.88M-12.56M17.49M-49.6M-16.97M-34.02M-119.49M-66.8M-30.3M-68.38M11.16M-38.63M-2.54M-40.68M-36.02M-78.1M-57.54M-32.08M-27.33M-29.42M-45.2M-42.9M-17.2M-28.3M
Net Interest Income-11.51M-13.03M-13.84M-569K694K-461K-1.84M-1.92M-922K-1.24M-3.95M-3.77M-4.3M-4.63M-4.39M-2.46M-385K-4.84M-6.14M0-11.26M-2.37M0-1.88M00-2.68M0000
Interest Income1.78M000694K00000000000049K859K01.68M1.88M000000000
Interest Expense13.28M13.03M13.84M569K0461K1.84M1.92M922K1.24M3.95M4.18M4.28M4.63M4.34M2.46M385K4.89M7M012.93M4.25M01.88M002.68M0000
Other Income/Expense28.94M20.43M20.5M1.02M295K-1.64M-619K1.9M3.42M-773K8.03M19.12M43.53M-65.87M-14.52M1.23M-1.63M-6.68M-6.89M-9.78M-11.16M38.81M-846K-1.11M871K1.96M2.68M1.2M-6.5M1.5M-900K
Pretax Income33.91M31.82M-19.48M-40.83M-17.12M15.89M11.8M-1.98M-13.44M16.26M-53.53M-20.61M-38.3M-124.07M-71.14M-32.73M-68.73M6.28M-45.63M-12.33M-51.84M2.78M-78.94M-58.65M-31.21M-25.37M-26.73M-44M-49.4M-15.7M-29.2M
Pretax Margin %93.61%61.01%-68.38%-858.15%-284.04%41.64%40.15%-10.79%-253.65%30.86%-962.08%-37.16%-203.02%-349.98%-210.58%-56.24%-204.3%6.38%-67.11%-14.63%-175.74%14.9%-2153.94%-240.26%-104.2%-146.84%-401.44%-1833.33%-784.13%-85.33%-811.11%
Income Tax104K103K-5.66M0-15K91K-1.5M0-98K1.66M000-14K-74K15K27K5.73M-383K003K001.17M709K-4K600K4.3M-1.3M800K
Effective Tax Rate %0.31%0.32%29.05%0%0.09%0.57%-12.72%0%0.73%10.22%0%0%0%0.01%0.1%-0.05%-0.04%91.24%0.84%0%0%0.11%0%0%-3.75%-2.79%0.01%-1.36%-8.7%8.28%-2.74%
Net Income31.51M31.71M-13.82M-40.83M-17.1M15.8M13.3M-1.98M-13.34M14.6M-53.53M-20.61M-38.3M-124.06M-71.06M-32.74M-68.76M550K-45.24M-12.33M-51.84M2.78M-78.94M-58.65M-33.25M-28.04M-29.41M-45.8M-47.2M-15.8M-29.1M
Net Margin %86.97%60.81%-48.52%-858.15%-283.79%41.4%45.25%-10.79%-251.8%27.7%-962.08%-37.16%-203.02%-349.94%-210.36%-56.26%-204.38%0.56%-66.55%-14.63%-175.74%14.89%-2153.94%-240.26%-111.01%-162.28%-441.69%-1908.33%-749.21%-85.87%-808.33%
Net Income Growth %1202.1%329.45%66.15%-138.72%-208.27%18.8%770.94%85.15%-191.42%127.27%-159.78%46.2%69.13%-74.57%-117.04%52.38%-12601.09%101.22%-267.07%76.22%-1965.46%103.52%-34.59%-76.42%-18.57%4.66%35.78%2.97%-198.73%45.7%-29.33%
Net Income (Continuing)33.81M31.71M-13.82M-40.83M-17.1M15.8M13.3M-1.98M-13.34M14.6M-53.53M-20.61M-38.3M-124.06M-71.06M-32.74M-68.76M550K-45.24M-12.33M-51.84M2.78M-78.94M-58.65M-33.25M-28.04M-29.41M-45.8M-47.2M-15.8M-29.1M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)1.811.46-1.65-4.04-1.980.650.78-0.88-1.590.73-8.89-3.50-6.64-28.54-21.99-20.73-73.880.97-102.11-28.90-162.079.00-279.09-234.39-141.77-123.42-136.34-260.70-330.11-119.86-268.67
EPS Growth %317.39%188.48%59.16%-104.04%-404.62%-16.67%188.64%44.65%-317.81%108.21%-154%47.29%76.73%-29.79%-6.08%71.94%-7716.49%100.95%-253.32%82.17%-1900.78%103.22%-19.07%-65.33%-14.87%9.48%47.7%21.03%-175.41%55.39%5.78%
EPS (Basic)-1.53-1.65-4.04-1.980.690.82-0.88-1.590.75-8.89-3.50-7.13-28.60-22.00-20.73-73.881.00-102.11-28.90-162.079.00-279.09-234.39-141.77-123.42-136.34-260.70-330.11-119.86-268.67
Diluted Shares Outstanding17.42M17.98M11.7M11.47M11.41M12.19M11.5M8.76M8.37M7.98M6.02M5.89M5.77M4.35M3.23M1.58M930.65K565.65K443.1K426.49K319.87K300.21K282.86K250.23K234.52K227.2K215.73K175.68K142.98K131.82K108.31K
Basic Shares Outstanding11.89M17.98M11.7M11.47M11.41M11.29M10.67M8.76M8.37M7.62M6.02M5.89M5.37M4.34M3.23M1.58M930.65K549.65K443.1K426.49K319.87K287.14K282.86K250.23K234.52K227.2K215.73K175.68K142.98K131.82K108.31K
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Binary Milestone Revenue Volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Lumpy Revenue Obscures Underlying Trends

As reported in recent financial filings, XOMA's revenue trajectory remains highly erratic, characterized by a 83.6% sequential decline in 2025Q4 followed by significant fluctuations, which underscores the inherent unpredictability of milestone-driven income streams compared to more stable, long-term commercial royalty payments from the company's diversified portfolio.

The extreme volatility in top-line performance suggests that XOMA's growth is currently tethered to the timing of clinical trial events rather than consistent commercial adoption of underlying assets. Investors should monitor whether the company can transition toward a higher proportion of sales-based royalties to smooth out these periodic revenue swings.

High Gross Margins Mask Inefficiency

Based on the company's reported figures, XOMA maintains exceptional gross margins consistently exceeding 90%, yet operating profitability remains inconsistent, as evidenced by the 2024Q4 operating margin of -83.2% which highlights the significant overhead required to manage a complex, early-stage portfolio of over 70 distinct royalty interests.

While the asset-light model avoids manufacturing costs, the high fixed-cost structure relative to current revenue suggests that the company has yet to achieve the necessary scale to leverage its corporate overhead. Future margin expansion appears contingent upon the successful commercialization of assets that require less intensive legal and monitoring resources.

Non-Operating Items Distort Net Income

According to historical income statements, XOMA's net income is frequently decoupled from operating performance, with significant quarterly swings such as the $14.1M profit in 2025Q3, largely driven by non-operating items and fair value adjustments rather than core royalty cash flows generated from the company's clinical asset base.

The reliance on non-recurring items makes GAAP net income a poor proxy for the underlying health of the business. Analysts should focus on adjusted metrics that strip out these accounting anomalies to better understand the true cash-generating capacity of the royalty portfolio.

Overhead Discipline Remains A Challenge

As indicated by recent quarterly data, SG&A expenses frequently consume a substantial portion of gross profit, with the company reporting $11.9M in SG&A during 2026Q1, which suggests that the cost of sourcing and managing early-stage biotech assets remains a persistent drag on overall corporate profitability.

The high level of professional fees and personnel costs required to maintain the portfolio warrants further investigation into the scalability of the current management model. Without a significant increase in royalty inflows, the current expense structure may continue to pressure the company's ability to generate consistent bottom-line growth.

XOMA — Frequently Asked Questions

Quick answers to the most common questions about buying XOMA stock.

What was XOMA Royalty Corp.'s (XOMA) revenue in 2025?

For fiscal year 2025, XOMA Royalty Corp. (XOMA) reported total revenue of $52.1M. This represents a 1348.6% increase compared to $3.6M in 1996.

Is XOMA Royalty Corp. (XOMA) profitable?

XOMA Royalty Corp. (XOMA) is profitable, generating $31.7M in net income for the fiscal year ending 2025 with a net profit margin of 60.8%.

What is XOMA Royalty Corp.'s operating profit margin?

XOMA Royalty Corp. (XOMA) reported an operating income of $11.4M, resulting in an operating profit margin of 21.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is XOMA Royalty Corp.'s gross profit and gross margin?

XOMA Royalty Corp. (XOMA) generated $49.2M in gross profit for the year, representing a gross profit margin of 94.3%. This demonstrates the company's core pricing power and production efficiency.